<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05095168</url>
  </required_header>
  <id_info>
    <org_study_id>CAN106-HV-101</org_study_id>
    <nct_id>NCT05095168</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Single Ascending Dose (SAD) of CAN106 Administered Intravenously (IV) in Healthy Subjects</brief_title>
  <official_title>Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Single Ascending Dose (SAD) of CAN106 Administered Intravenously (IV) in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CANbridge Life Sciences Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CANbridge Life Sciences Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single site, single dose escalation study in healthy subject with CAN106. The study&#xD;
      is to assess the safety and tolerability of single escalating doses of CAN106; to&#xD;
      characterize the PK and PD profile of CAN106; and to evaluate the immunogenicity of CAN106&#xD;
      injection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 8, 2021</start_date>
  <completion_date type="Anticipated">May 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of subjects with dose-limiting toxicity (DLTs)</measure>
    <time_frame>6-months after dosing</time_frame>
    <description>TEAEs will be categorized as per the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v5.0 criteria.&#xD;
a DLT is defined as one subject with a Grade 3 AE or higher, that are assessed as drug-related by the site investigator.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events (AEs)</measure>
    <time_frame>6-months after dosing</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of severe adverse events (SAEs)</measure>
    <time_frame>6-months after dosing</time_frame>
    <description>Any untoward medical occurrence that at any dose:&#xD;
Results in death,&#xD;
Is life-threatening,&#xD;
Requires inpatient hospitalization or prolongation of existing hospitalization,&#xD;
Results in persistent or significant disability/incapacity, or&#xD;
Is a congenital anomaly/birth defect. (ICH E6 (R2))</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameters - tmax</measure>
    <time_frame>6-months after dosing</time_frame>
    <description>time to reach maximum of concentration (days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters-Cmax</measure>
    <time_frame>6-months after dosing</time_frame>
    <description>peak plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters - AUC0-t</measure>
    <time_frame>6-months after dosing</time_frame>
    <description>Area under the plasma concentration versus time curve to the last visit (AUCt)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters - t1/2</measure>
    <time_frame>6-months after dosing</time_frame>
    <description>terminal elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD endpoints-free C5</measure>
    <time_frame>6-months after dosing</time_frame>
    <description>maximal change from baseline in free C5 concentrations at each of scheduled post baseline assessment time-points (µg/ml);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD endpoints-CH50</measure>
    <time_frame>6-months after dosing</time_frame>
    <description>maximal change from baseline total complement activity (CH50) at each of scheduled post baseline assessment time-points (%);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD endpoints-total C5</measure>
    <time_frame>6-months after dosing</time_frame>
    <description>meausure the absolute change from baseline in total C5 concentrations at each of scheduled post baseline assessment time-points (µg/ml);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>6-months after dosing</time_frame>
    <description>Anti-drug Antibody (ADA) titers</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">31</enrollment>
  <condition>PNH</condition>
  <arm_group>
    <arm_group_label>Single Ascending Dose (SAD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the SAD arm subjects will be sequentially included in one of up to six cohorts (dose levels). Additional subjects may be added in any cohort if necessary.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In the SAD arm subjects will be sequentially included in one of up to six cohorts (dose levels). In higher dose levels, subjects will be randomized to receive the treatment or placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAN106</intervention_name>
    <description>CAN106 is a selective inhibitor of complement activation, which binds to the complement component C5.</description>
    <arm_group_label>Single Ascending Dose (SAD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must be able to understand and provide informed consent.&#xD;
&#xD;
          -  Males or females, between 21 and 45 years of age, inclusive;&#xD;
&#xD;
          -  Body mass index must be within the range of 18.5 to 32.0 kg/m2;&#xD;
&#xD;
          -  12-lead electrocardiogram (ECG) within normal limits with no clinically significant&#xD;
             abnormalities in the opinion of the Investigator；&#xD;
&#xD;
          -  Systolic blood pressure ≤140 mmHg and a diastolic blood pressure of ≤ 90 mmHg after 5&#xD;
             minutes with supine rest；&#xD;
&#xD;
          -  non-pregnancy&#xD;
&#xD;
          -  meningococcal vaccinations for at least 2 weeks before dosing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Disease or conditions interfere with participating the trial&#xD;
&#xD;
          -  Active serious mental illness or psychiatric disorder&#xD;
&#xD;
          -  clinically relevant abnormal test results in hepatic function&#xD;
&#xD;
          -  unacceptable CBC lab test&#xD;
&#xD;
          -  asymptomatic complement deficiency&#xD;
&#xD;
          -  Any other clinical safety laboratory test&#xD;
&#xD;
          -  HIV, HBV, HCV positive&#xD;
&#xD;
          -  Alcohol and drug abuse&#xD;
&#xD;
          -  etc.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 22, 2021</study_first_submitted>
  <study_first_submitted_qc>October 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2021</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

